Oxygen-rich synergistic multi-mode cold therapy cabin system

Abstract

The application discloses an oxygen-rich cooperative multi-mode cold therapy cabin system, which comprises a refrigeration system, an environmental control system, a movable local enhanced cold therapy system, an in-cabin monitoring system, a photodynamic therapy system and a two light distribution structure, wherein the refrigeration system, the environmental control system, the movable local enhanced cold therapy system, the in-cabin monitoring system and the photodynamic therapy system are connected to a main controller; the application provides an ultralow-temperature cryotherapy equipment which can combine oxygen-rich recovery, photodynamic therapy and local position enhanced cold therapy; the refrigeration system cooperates with the environmental control system to realize a wide temperature range of -40 DEG C to -110 DEG C in the cold therapy cabin and realizes a rich and nourishing treatment environment; in combination with the photodynamic therapy system, different physical factors can be provided by the oxygen-rich cooperative multi-mode cold therapy cabin system according to different treatment purposes of patients, so that the treatment effect of the treatment purpose can be achieved.

Description

[0001] This application is a divisional application of application 202410225499X, filed on 2024-02-29, by the applicant Xiamen Nazhike Biotechnology Co., Ltd. Technical Field

[0002] This invention relates to the field of physiotherapy system technology, specifically to an oxygen-enriched synergistic multi-mode cryotherapy chamber system. Background Technology

[0003] Cryotherapy promotes bodily recovery by stimulating the body with ultra-low-temperature liquid nitrogen spray or air. The timing of cryotherapy intervention has varying effects on improving bodily functions, repairing damage, and preventing structural injuries in individuals undergoing high-intensity exercise. Pre-training cryotherapy reduces the risk of oxidative stress caused by high-intensity exercise. Cryotherapy can suppress post-exercise inflammation by increasing anti-inflammatory interleukins and reducing the secretion of pro-inflammatory signaling molecules. Cryotherapy can reduce osteoclast production, promoting bone formation and reducing bone resorption, thus positively impacting athletes. Cryotherapy increases resting energy expenditure and activates non-shivering thermogenesis in brown adipose tissue and skeletal muscle, increasing lipid metabolism and adipose tissue thermogenesis. Cryotherapy effectively stimulates the parasympathetic nervous system, increasing lactate clearance and boosting oxygen uptake during subsequent exercise. Cryotherapy can improve sleep quality by promoting parasympathetic activity. Cryotherapy effectively relieves delayed onset muscle soreness (DOMS), reduces muscle damage, and facilitates muscle strength recovery after eccentric exercise. Pre-exercise cryotherapy can cause hormonal changes, lower body temperature, and reduce perceived fatigue and pain, which can effectively improve athletes' performance.

[0004] Oxygen-enriched environments refer to environments with oxygen levels exceeding a certain standard. The therapeutic effects of oxygen-enriched environments on the human body include improving immunity, promoting blood circulation, improving brain function, promoting cardiovascular health, improving skin condition, and enhancing athletic performance.

[0005] Light is an electromagnetic wave. When it shines on and is absorbed by the human body, different biological effects are produced within the body depending on the energy of the incident photons. Treatments that utilize this effect are called photodynamic therapy.

[0006] There is a need for an ultra-low temperature cryotherapy device that combines oxygen-enriched recovery, photodynamic therapy, and localized enhanced cryotherapy. Depending on the patient's treatment goals, the provided oxygen-enriched synergistic multi-mode cryotherapy chamber system allocates different physical factors to achieve the desired therapeutic effect. Summary of the Invention

[0007] The purpose of this invention is to provide an oxygen-enriched, synergistic multi-mode cryotherapy chamber system to address the issues raised in the background art regarding ultra-low temperature cryotherapy devices that combine oxygen-enriched recovery, photodynamic therapy, and locally enhanced cryotherapy. Depending on the patient's treatment objectives, the provided oxygen-enriched, synergistic multi-mode cryotherapy chamber system allocates different physical factors to achieve the desired therapeutic effect.

[0008] To achieve the above objectives, the present invention adopts the following technical solution:

[0009] An oxygen-enriched, multi-mode cryotherapy chamber system includes a refrigeration system, an environmental control system, a movable local enhanced cryotherapy system, an in-chamber monitoring system, a photodynamic therapy system, and a dual-light distribution structure. The refrigeration system, environmental control system, movable local enhanced cryotherapy system, in-chamber monitoring system, and photodynamic therapy system are connected to a main controller. The main controller, according to human-machine interaction settings, acts on each system to achieve cryotherapy combining oxygen-enriched recovery, photodynamic therapy, and local enhanced cryotherapy. The system also includes refrigeration pipes arranged outside the chamber and connected to the refrigeration system, environmental control pipes arranged inside the chamber and connected to the environmental control system, and local cooling pipes arranged inside the chamber and connected to the movable local enhanced cryotherapy system.

[0010] The refrigeration system uses single-stage compression to achieve a wide temperature range of -40℃ to -110℃. Different refrigerants are mixed to form multi-component refrigerants. The different boiling points of the mixed refrigerants and their different boiling points under the same pressure enable the separation of refrigerants.

[0011] The mixed refrigerant uses a non-azeotropic mixture of R290 / R23 / R14. After being compressed and discharged by a single-stage compressor, it enters the condenser-evaporator for condensation. After condensation, the mixed refrigerant forms a multiphase flow with the uncondensed refrigerant. The multiphase flow is separated by a gas-liquid separator. The mixed refrigerants with different boiling points are condensed separately to form a liquid phase high-temperature stage refrigerant (R290), a liquid phase medium-temperature stage refrigerant (R23), and a liquid phase low-temperature stage refrigerant (R14). The liquid phase refrigerant evaporates in the evaporator, achieving heat absorption and cooling. The different liquid phase refrigerants formed after passing through the gas-liquid separator and the low-temperature condenser-evaporator enter the terminal evaporator respectively to achieve different cooling temperatures. The evaporator covers the outside of the enclosed compartment. Through heat exchange, the temperature inside the compartment can be reduced to -40℃ to -110℃.

[0012] The boiling point of the liquid phase high-temperature working fluid (R290) is -42.17℃, the boiling point of the liquid phase medium-temperature working fluid (R23) is -82.2℃, and the boiling point of the liquid phase low-temperature working fluid (R14) is -128℃.

[0013] The environmental control system is a closed-loop cryotherapy chamber environment control system. The chamber itself is physically isolated from the surrounding environment, forming a completely enclosed physical space. During treatment, the environmental control system manages the environment within this completely enclosed space. The patient is situated within this space, and the environmental control measures treatment and survival parameters to ensure safe and effective treatment. Treatment parameters include, but are not limited to, temperature, light intensity, treatment time, and oxygen levels. Survival parameters include, but are not limited to, carbon dioxide concentration, humidity, and chamber pressure. The system controls these treatment and survival parameters. The system is controlled through various operating modes, including but not limited to oxygen generation mode, drying and CO2 filtration mode, environmental replacement mode, and depressurization mode. The oxygen generation mode consists of an oxygen generation channel, the drying and CO2 filtration mode consists of a drying and CO2 filtration channel, the environmental replacement mode consists of an environmental replacement channel, and the depressurization mode consists of a depressurization channel. The oxygen generation channel, drying and CO2 filtration channel, and environmental replacement channel are all channels for outside gas to enter the cabin. They share an evaporative heat exchanger and a drying condenser to cool and dry the gas in the pipelines. The depressurization channel is the channel for the gas inside the cabin to exit the cabin.

[0014] 1. Oxygen generation channel

[0015] The environmental control system maintains the oxygen concentration within the chamber within an oxygen-enriched range, typically between 21% and 24%, via an oxygen generation channel. After the oxygen-enriched concentration is designed through human-machine interaction, the oxygen concentration sensor (OS) monitors changes in the chamber's oxygen concentration and maintains it at the set concentration by controlling the oxygen generation channel.

[0016] The Oxygen Generator (OG) draws air from the environment, passes it through an internal molecular sieve, and outputs pressurized oxygen at a concentration controlled at 93% ± 3%. The oxygen flows through the chamber's electrically adjustable solenoid valve SOV-2, and the main controller controls the oxygen flow rate by adjusting the opening of SOV-2. The pressurized oxygen, with its flow rate controlled, flows to the IN_2 port of the dryer / condenser DCS for filtration and drying to reduce its humidity. The low-humidity pressurized oxygen output from the OUT_2 port of the dryer / condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, where its temperature is reduced to the chamber's ambient temperature. It is then output back into the chamber via the OUT_2 port of the evaporative heat exchanger EHX-2 (with the inlet solenoid valve SOV-10 open and the enhanced cryotherapy solenoid valve SOV-5 closed).

[0017] The cryotherapy chamber is a completely enclosed physical space during treatment. The introduction of low-temperature, low-humidity, pressurized oxygen increases the internal pressure. The enclosed cryotherapy chamber described in this patent maintains an internal pressure of ≤0.08 MPa during treatment, i.e., a working pressure of 0.08 MPa, which is considered an atmospheric pressure vessel and poses no safety hazard.

[0018] To maintain the cabin pressure at the working pressure during oxygen production, cabin pressure sensor P_1 detects a deviation from the working pressure and initiates cabin depressurization. During depressurization, cabin air passes through cabin ventilation duct CVP-1, is heated by heater HTR to the temperature range of the suction medium of the low-temperature oil-free air compressor LAC, and is then discharged to the ambient atmosphere through cabin depressurization solenoid valve SOV-3.

[0019] The oxygen generation channel is controlled by the main controller to maintain the oxygen concentration in the chamber at the set level during treatment and to maintain the pressure in the chamber at the working pressure (≤0.08Mpa).

[0020] Mathematical model of oxygen concentration inside the cabin:

[0021] Initial parameters inside the chamber: pressure P0, gas mass m0, relative molecular mass M0, gas constant R0, oxygen concentration n0.

[0022] After a certain time t, the parameters inside the cabin are: pressure P t gas mass m t relative molecular weight M t Gas constant R t Oxygen concentration n t oxygen mass m at time t o2t ;

[0023] The airflow q1 is output to the cabin via OUT_2 of the evaporative heat exchanger EHX-2;

[0024] The exhaust flow rate q2 output to the ambient atmosphere by the cabin depressurization solenoid valve SOV-3;

[0025] The oxygen production flow rate q3 output by the oxygen concentrator OG;

[0026] The volume V inside the cryotherapy chamber; ρ is the density of dry air, ρ o2 Dry oxygen density

[0027]

[0028] Based on the above control of air intake and exhaust in the cabin, the instantaneous changes in the total amount of gas and the mass of oxygen in the cabin at a certain time t can be obtained as follows:

[0029]

[0030] Wherein; dm is the mass of the gas mixture at any time; dm1 is the mass of the air entering the chamber after being cooled by the evaporator; and dm2 is the mass of the air discharged from the chamber to the atmosphere through the pressure relief valve.

[0031] The mass of the gas and the mass of oxygen inside the cabin at a certain time t are:

[0032]

[0033] Assuming that the mass of all gaseous substances except oxygen remains constant during the oxygen supply process, then the relative molecular mass and gas constant of the gas in the chamber at time t are:

[0034]

[0035] Substituting formulas 1-4 above into the gas state equation, we can obtain the cabin pressure and oxygen concentration at time t as follows:

[0036]

[0037] Therefore, as can be seen from the above formula, the system main controller can control the intake air flow q1 output from OUT_2 of the evaporative heat exchanger EHX-2 to the chamber and the exhaust air flow q2 output from the chamber pressure relief solenoid valve SOV-3 to the ambient atmosphere within a certain period of time, so that the oxygen in the chamber can be maintained at the set concentration and the pressure in the chamber can be maintained at the working pressure (≤0.08Mpa) during the treatment.

[0038] 2. Drying and CO2 filtration channels

[0039] 2.1 CO2 Filtration

[0040] Carbon dioxide is a metabolic byproduct of human metabolism. The carbon dioxide content in inhaled air is only 0.03–0.04%; however, in exhaled air, the concentration increases approximately 100 times, reaching 3–4%. In completely enclosed cryotherapy chambers during treatment, the CO2 produced by the patient's metabolism will cause an increase in the CO2 content in the confined space. The normal concentration of CO2 in the air is 0.03%. When the oxygen concentration in the air is ≤17%, the CO2 concentration exceeds 4%, causing respiratory system disturbances, with deeper and more frequent breathing. When oxygen is sufficient, a CO2 concentration of 5% is harmless. However, when the CO2 concentration exceeds 10%, it can lead to coma or even suffocation. Therefore, CO2 concentration control is essential for completely enclosed cryotherapy chambers.

[0041] The environmental control system keeps the carbon dioxide (CO2) concentration inside the cabin below 1% through drying and CO2 filtration channels.

[0042] The CO2 concentration sensor CDS monitors the CO2 concentration inside the chamber. When the CO2 concentration inside the chamber is >0.5%, the main controller controls the drying and CO2 filtration channels to maintain the CO2 concentration ≤0.5%.

[0043] Air with excessive carbon dioxide concentration inside the cabin is heated to the suction medium temperature range of the low-temperature oil-free air compressor LAC via the cabin ventilation duct CVP-1 and heater HTR. It then flows through the oil-free air compressor LAC and through the cabin drying and CO2 filtration solenoid valve SOV-1 (SOV-1 open, SOV-3 closed) to the carbon dioxide filter CO2F, where it adsorbs carbon dioxide from the air. The CO2 filter CO2F uses lithium hydroxide particles as the filter medium, and its reaction process is as follows:

[0044] 2LiOH + 2H₂O → 2LiOH·H₂O

[0045] 2LiOH·H2O + CO2 → Li2CO3 + 3H2O

[0046] Overall reaction equation:

[0047] 2LiOH + CO2 → Li2CO3 + H2O

[0048] The filtered air flows to the IN_2 port of the dryer-condenser DCS for further filtration and drying to reduce humidity. The low-humidity air output from the OUT_2 port of the dryer-condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, where its temperature is lowered to the ambient temperature inside the chamber. It is then output back into the chamber via the OUT_2 port of the evaporative heat exchanger EHX-2 (with the inlet solenoid valve SOV-10 open and the enhanced cryotherapy solenoid valve SOV-5 closed). Through this drying and CO2 filtration process, the excessive carbon dioxide concentration in the chamber is gradually reduced to ≤0.5%.

[0049] 2.2 Drying

[0050] Excessive humidity can cause discomfort for patients undergoing cryotherapy in a cryotherapy chamber. For a completely sealed cryotherapy chamber during treatment, the reasons for increased humidity are: 1. Humidity load of the external environment; 2. Humidity load generated by the human body's metabolic processes. Therefore, the humidity inside the chamber should be controlled during treatment.

[0051] The environmental control system keeps the relative humidity inside the cabin below 30% through drying and CO2 filtration channels.

[0052] The relative humidity sensor HS monitors the relative humidity inside the chamber. When the relative humidity inside the chamber is greater than 25%, the main controller controls the relative humidity to ≤25% by controlling the drying and CO2 filtration channels.

[0053] Air with excessive humidity inside the chamber is heated by the heater HTR to the suction medium temperature range of the low-temperature oil-free air compressor LAC through the chamber ventilation duct CVP-1. It then flows through the oil-free air compressor LAC and through the chamber drying and CO2 filtering solenoid valve SOV-1 (SOV-1 open, SOV-3 closed) to the CO2 filter CO2F, where carbon dioxide is adsorbed. The filtered air then flows to the IN_2 port of the dryer-condenser DCS for further filtration and humidity reduction. The low-humidity air output from the OUT_2 port of the dryer-condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, where its temperature is lowered to the chamber's ambient temperature. It then exits into the chamber through the OUT_2 port of the evaporative heat exchanger EHX-2 (inlet solenoid valve SOV-10 open, enhanced cryotherapy solenoid valve SOV-5 closed). Through the aforementioned drying and CO2 filtration channels, the relative humidity inside the chamber is gradually controlled to ≤25%.

[0054] In summary, according to 2.1 and 2.2, when the relative humidity inside the cabin is greater than 25% or the carbon dioxide concentration inside the cabin is greater than 0.5%, the main control will activate the drying and CO2 filtration channels.

[0055] 3. Environmental replacement channel

[0056] The environmental replacement channel typically operates outside of treatment periods, primarily to replace the air within the enclosed cryotherapy chamber to remove airborne particles or substances that cause unpleasant olfactory experiences generated during the treatment of the patient above.

[0057] The oil-free air compressor AC draws pressurized air from the environment, which flows through the chamber displacement solenoid valve SOV-4. The main controller opens SOV-4, directing the pressurized air to the IN_2 port of the dryer-condenser DCS for filtration and drying to reduce humidity. The low-humidity pressurized air from the OUT_2 port of the dryer-condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, lowering its temperature to the chamber's ambient temperature. It then exits through the OUT_2 port of the evaporative heat exchanger EHX-2 back into the chamber (with the inlet solenoid valve SOV-10 open and the enhanced cooling solenoid valve SOV-5 closed).

[0058] To maintain the cabin pressure at the operating pressure, cabin pressure sensor P_1 detects pressure deviations from the operating pressure and initiates cabin depressurization. During depressurization, cabin air flows through cabin ventilation duct CVP-1, is heated by heater HTR to the suction medium temperature range of the low-temperature oil-free air compressor LAC, and is then discharged to the ambient atmosphere via cabin depressurization solenoid valve SOV-3. The operating pressure is the same as the cabin operating pressure described in section 1 (Oxygen Generation Channel): 0.08 MPa.

[0059] 4. Pressure relief channel

[0060] The working pressure of the chamber mentioned in section 1, Oxygen Generation Channel, is 0.08 MPa.

[0061] Whether during treatment or not, when the pressure monitored by the chamber pressure sensor P_1 deviates from the working pressure, the chamber pressure relief channel is activated.

[0062] The air inside the cabin is heated to the temperature range of the suction medium of the low-temperature oil-free air compressor LAC by the heater HTR through the cabin ventilation duct CVP-1. The air is then discharged to the ambient atmosphere through the cabin pressure relief solenoid valve SOV-3 by the oil-free air compressor LAC, so that the cabin pressure is maintained at the working pressure (≤0.08Mpa).

[0063] The in-cabin monitoring system includes an oxygen sensor, a CO2 sensor, a pressure sensor, a humidity sensor, a temperature sensor, and an illuminance sensor. It monitors the current values ​​of the treatment parameters and survival parameters to assist in the control of the cooling system, environmental control system, photodynamic therapy system, and mobile enhanced therapy system, thereby achieving safe and effective treatment.

[0064] The photodynamic therapy system described is a multi-mode cryotherapy chamber photodynamic light source with a secondary light distribution and distribution structure that reshapes the emitted light. The photodynamic light source inside the chamber is a multi-spectral light source composed of 460nm, 630nm, and 525nm wavelengths. The light source used in the photodynamic therapy system is as follows: multiple multi-wavelength light chips are packaged into the same light source module. The light source module uses a compound eye lens optical system for secondary light distribution to reshape the unevenly distributed incident circular light spot into a uniformly illuminated rectangular light spot. The light source module and the compound eye lens optical system constitute a light source unit. A certain number of light source units with intervals are distributed along the circumference and longitudinal direction of the chamber to form a light source unit array. The light source unit array solves the problems of light intensity, uniformity, and illumination area inside the chamber, enabling patients inside the chamber to receive photodynamic therapy with uniform illumination.

[0065] The portable local enhanced cryotherapy system comprises a portable cryotherapy chamber containing a local enhanced cryotherapy structure that provides enhanced cryotherapy to specific areas of the body during treatment within the chamber. The local enhanced terminal (MLEC), controlled by this structure, treats random locations on the body in the vertical direction. The MLEC's cooling source is an environmental control system, which selects a local enhanced cryotherapy channel before entering the chamber via the system's displacement channel to achieve enhanced cryotherapy. The MLEC can move vertically to provide cryotherapy to random locations on the body in the vertical direction. The MLEC also features an open nozzle to provide enhanced low-temperature spray cryotherapy to specific areas.

[0066] The oil-free air compressor AC draws pressurized air from the environment, which flows through the chamber displacement solenoid valve SOV-4. The main controller opens SOV-4, directing the pressurized air to the IN_2 port of the dryer-condenser DCS for filtration and drying to reduce humidity. The low-humidity pressurized air from the OUT_2 port of the dryer-condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, lowering its temperature to the chamber's ambient temperature. It then exits through the OUT_2 port of the evaporative heat exchanger EHX-2 to the portable local enhanced cryotherapy terminal MLEC for local enhanced cryotherapy (inlet solenoid valve SOV-10 is closed, enhanced cryotherapy solenoid valve SOV-5 is open).

[0067] To maintain the cabin pressure at the operating pressure, cabin pressure sensor P_1 detects a deviation from the operating pressure and initiates cabin depressurization. During depressurization, cabin air flows through cabin ventilation duct CVP-1, is heated by heater HTR to the temperature range of the suction medium of the low-temperature oil-free air compressor LAC, and is then discharged to the ambient atmosphere via cabin depressurization solenoid valve SOV-3. The operating pressure is the same as the cabin operating pressure described in section 2.1 (Oxygen Generation Channel), which is 0.08 MPa.

[0068] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0069] The system of this invention includes a refrigeration system, an environmental control system, a movable local enhanced cryotherapy system, an in-cabin monitoring system, a photodynamic therapy system, and a dual-light distribution structure. It provides an ultra-low temperature cryotherapy device that can combine oxygen-enriched recovery, photodynamic therapy, and local enhanced cryotherapy. The refrigeration system can provide treatment temperatures in a wide temperature range of -40℃ to -110℃, and works with an oxygen-generating channel to create a rich treatment environment. Combined with the photodynamic therapy system, the oxygen-enriched synergistic multi-mode cryotherapy chamber system can allocate different physical factors according to the patient's different treatment goals to achieve the desired therapeutic effect. Attached Figure Description

[0070] Figure 1 This is a schematic diagram of the overall circuit structure of the present invention.

[0071] Figure 2 This is a schematic diagram of the circulating cooling channel traversing channel 1 in Embodiment 2 of the present invention;

[0072] Figure 3 This is a schematic diagram of the circulating cooling channel traversing channel 2 in Embodiment 3 of the present invention;

[0073] Figure 4 This is a schematic diagram of the circulating cooling channel traversing channel 3 in Embodiment 4 of the present invention;

[0074] Figure 5 This is a schematic diagram of the oxygen generation channel traversal in Embodiment 1 of the present invention;

[0075] Figure 6 This is a schematic diagram of the drying and CO2 filtration channel traversal in Embodiment 1 of the present invention;

[0076] Figure 7 This is a schematic diagram of the environment permutation traversal channel in Embodiment 1 of the present invention;

[0077] Figure 8 This is a schematic diagram of the pressure relief channel traversal in Embodiment 1 of the present invention;

[0078] Figure 9 This is a schematic diagram of the local enhanced cryotherapy channel traversal in Embodiment 1 of the present invention. Detailed Implementation

[0079] The technical solution of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the protection scope of the present invention.

[0080] Example 1

[0081] An oxygen-enriched, multi-mode cryotherapy chamber system includes a refrigeration system, an environmental control system, a movable local enhanced cryotherapy system, an in-chamber monitoring system, a photodynamic therapy system, and a dual-light distribution structure. The refrigeration system, environmental control system, movable local enhanced cryotherapy system, in-chamber monitoring system, and photodynamic therapy system are connected to a main controller. The main controller, according to human-machine interaction settings, acts on each system to achieve cryotherapy combining oxygen-enriched recovery, photodynamic therapy, and local enhanced cryotherapy. The system also includes refrigeration pipes arranged outside the chamber and connected to the refrigeration system, environmental control pipes arranged inside the chamber and connected to the environmental control system, and local cooling pipes arranged inside the chamber and connected to the movable local enhanced cryotherapy system.

[0082] The refrigeration system uses single-stage compression to achieve a wide temperature range of -40℃ to -110℃. Different refrigerants are mixed to form multi-component refrigerants. The different boiling points of the mixed refrigerants and their different boiling points under the same pressure enable the separation of refrigerants.

[0083] The mixed refrigerant uses a non-azeotropic mixture of R290 / R23 / R14. After being compressed and discharged by a single-stage compressor, it enters the condenser-evaporator for condensation. After condensation, the mixed refrigerant forms a multiphase flow with the uncondensed refrigerant. The multiphase flow is separated by a gas-liquid separator. The mixed refrigerants with different boiling points are condensed separately to form a high-temperature liquid stage (R290), a medium-temperature liquid stage (R23), and a low-temperature liquid stage (R14). The liquid stage refrigerant evaporates in the evaporator, achieving heat absorption and cooling. The different liquid stages formed after passing through the high-temperature and gas-liquid separators and the low-temperature condenser-evaporator enter the terminal evaporator to achieve different cooling temperatures. The evaporator covers the outside of the enclosed compartment and, through heat exchange, can lower the temperature inside the compartment to within -40℃ to -110℃.

[0084] The boiling point of the liquid phase high-temperature working fluid (R290) is -42.17℃, the boiling point of the liquid phase medium-temperature working fluid (R23) is -82.2℃, and the boiling point of the liquid phase low-temperature working fluid (R14) is -128℃.

[0085] The environmental control system is a closed-loop cryotherapy chamber environment control system. The chamber itself is physically isolated from the surrounding environment, forming a completely enclosed physical space. During treatment, the environmental control system manages the environment within this completely enclosed space. The patient is situated within this space, and the environmental control measures treatment and survival parameters to ensure safe and effective treatment. Treatment parameters include, but are not limited to, temperature, light intensity, treatment time, and oxygen levels. Survival parameters include, but are not limited to, carbon dioxide concentration, humidity, and chamber pressure. The system controls these treatment and survival parameters. The system is controlled through various operating modes, including but not limited to oxygen generation mode, drying and CO2 filtration mode, environmental replacement mode, and depressurization mode. The oxygen generation mode consists of an oxygen generation channel, the drying and CO2 filtration mode consists of a drying and CO2 filtration channel, the environmental replacement mode consists of an environmental replacement channel, and the depressurization mode consists of a depressurization channel. The oxygen generation channel, drying and CO2 filtration channel, and environmental replacement channel are all channels for outside gas to enter the cabin. They share an evaporative heat exchanger and a drying condenser to cool and dry the gas in the pipelines. The depressurization channel is the channel for the gas inside the cabin to exit the cabin.

[0086] 1. Oxygen generation channel

[0087] like Figure 5 The bold lines shown represent the oxygen generation channel traversal channels.

[0088] The environmental control system maintains the oxygen concentration within the chamber within an oxygen-enriched range, typically between 21% and 24%, via an oxygen generation channel. After the oxygen-enriched concentration is designed through human-machine interaction, the oxygen concentration sensor (OS) monitors changes in the chamber's oxygen concentration and maintains it at the set concentration by controlling the oxygen generation channel.

[0089] The Oxygen Generator (OG) draws air from the environment, passes it through an internal molecular sieve, and outputs pressurized oxygen at a concentration controlled at 93% ± 3%. The oxygen flows through the chamber's electrically adjustable solenoid valve SOV-2, and the main controller controls the oxygen flow rate by adjusting the opening of SOV-2. The pressurized oxygen, with its flow rate controlled, flows to the IN_2 port of the dryer / condenser DCS for filtration and drying to reduce its humidity. The low-humidity pressurized oxygen output from the OUT_2 port of the dryer / condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, where its temperature is reduced to the chamber's ambient temperature. It is then output back into the chamber via the OUT_2 port of the evaporative heat exchanger EHX-2 (with the inlet solenoid valve SOV-10 open and the enhanced cryotherapy solenoid valve SOV-5 closed).

[0090] The cryotherapy chamber is a completely enclosed physical space during treatment. The introduction of low-temperature, low-humidity, pressurized oxygen increases the internal pressure. The enclosed cryotherapy chamber described in this patent maintains an internal pressure of ≤0.08 MPa during treatment, i.e., a working pressure of 0.08 MPa, which is considered an atmospheric pressure vessel and poses no safety hazard.

[0091] To maintain the cabin pressure at the working pressure during oxygen production, cabin pressure sensor P_1 detects a deviation from the working pressure and initiates cabin depressurization. During depressurization, cabin air passes through cabin ventilation duct CVP-1, is heated by heater HTR to the temperature range of the suction medium of the low-temperature oil-free air compressor LAC, and is then discharged to the ambient atmosphere through cabin depressurization solenoid valve SOV-3.

[0092] The oxygen generation channel is controlled by the main controller to maintain the oxygen concentration in the chamber at the set level during treatment and to maintain the pressure in the chamber at the working pressure (≤0.08Mpa).

[0093] Mathematical model of oxygen concentration inside the cabin:

[0094] Initial parameters inside the chamber: pressure P0, gas mass m0, relative molecular mass M0, gas constant R0, oxygen concentration n0.

[0095] After a certain time t, the parameters inside the cabin are: pressure P t gas mass m t relative molecular weight M t Gas constant R t Oxygen concentration n tThe oxygen mass m at time t o2t ;

[0096] The airflow q1 is output to the cabin via OUT_2 of the evaporative heat exchanger EHX-2;

[0097] The exhaust flow rate q2 output to the ambient atmosphere by the cabin depressurization solenoid valve SOV-3;

[0098] The oxygen production flow rate q3 output by the oxygen concentrator OG;

[0099] The volume V inside the cryotherapy chamber; ρ is the density of dry air, ρ o2 Dry oxygen density

[0100]

[0101] Based on the above control of air intake and exhaust in the cabin, the instantaneous changes in the total amount of gas and the mass of oxygen in the cabin at a certain time t can be obtained as follows:

[0102]

[0103] Wherein; dm is the mass of the gas mixture at any time; dm1 is the mass of the air entering the chamber after being cooled by the evaporator; and dm2 is the mass of the air discharged from the chamber to the atmosphere through the pressure relief valve.

[0104] The mass of the gas and the mass of oxygen inside the cabin at a certain time t are:

[0105]

[0106] Assuming that the mass of all gaseous substances except oxygen remains constant during the oxygen supply process, then the relative molecular mass and gas constant of the gas in the chamber at time t are:

[0107]

[0108] Substituting formulas 1-4 above into the gas state equation, we can obtain the cabin pressure and oxygen concentration at time t as follows:

[0109]

[0110] Therefore, as can be seen from the above formula, the system main controller can control the intake air flow q1 output from OUT_2 of the evaporative heat exchanger EHX-2 to the chamber and the exhaust air flow q2 output from the chamber pressure relief solenoid valve SOV-3 to the ambient atmosphere within a certain period of time, so that the oxygen in the chamber can be maintained at the set concentration and the pressure in the chamber can be maintained at the working pressure (≤0.08Mpa) during the treatment.

[0111] 2. Drying and CO2 filtration channels

[0112] like Figure 6The bold lines shown represent the drying and CO2 filtration channels.

[0113] 2.1 CO2 Filtration

[0114] Carbon dioxide is a metabolic byproduct of human metabolism. The carbon dioxide content in inhaled air is only 0.03–0.04%; however, in exhaled air, the concentration increases approximately 100 times, reaching 3–4%. In completely enclosed cryotherapy chambers during treatment, the CO2 produced by the patient's metabolism will cause an increase in the CO2 content in the confined space. The normal concentration of CO2 in the air is 0.03%. When the oxygen concentration in the air is ≤17%, the CO2 concentration exceeds 4%, causing respiratory system disturbances, with deeper and more frequent breathing. When oxygen is sufficient, a CO2 concentration of 5% is harmless. However, when the CO2 concentration exceeds 10%, it can lead to coma or even suffocation. Therefore, CO2 concentration control is essential for completely enclosed cryotherapy chambers.

[0115] The environmental control system keeps the carbon dioxide (CO2) concentration inside the cabin below 1% through drying and CO2 filtration channels.

[0116] The CO2 concentration sensor CDS monitors the CO2 concentration inside the chamber. When the CO2 concentration inside the chamber is >0.5%, the main controller controls the drying and CO2 filtration channels to maintain the CO2 concentration ≤0.5%.

[0117] Air with excessive carbon dioxide concentration inside the cabin is heated to the suction medium temperature range of the low-temperature oil-free air compressor LAC via the cabin ventilation duct CVP-1 and heater HTR. It then flows through the oil-free air compressor LAC and through the cabin drying and CO2 filtration solenoid valve SOV-1 (SOV-1 open, SOV-3 closed) to the carbon dioxide filter CO2F, where it adsorbs carbon dioxide from the air. The CO2 filter CO2F uses lithium hydroxide particles as the filter medium, and its reaction process is as follows:

[0118] 2LiOH + 2H₂O → 2LiOH·H₂O

[0119] 2LiOH·H2O + CO2 → Li2CO3 + 3H2O

[0120] Overall reaction equation:

[0121] 2LiOH + CO2 → Li2CO3 + H2O

[0122] The filtered air flows to the IN_2 port of the dryer-condenser DCS for further filtration and drying to reduce humidity. The low-humidity air output from the OUT_2 port of the dryer-condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, where its temperature is lowered to the ambient temperature inside the chamber. It is then output back into the chamber via the OUT_2 port of the evaporative heat exchanger EHX-2 (with the inlet solenoid valve SOV-10 open and the enhanced cryotherapy solenoid valve SOV-5 closed). Through this drying and CO2 filtration process, the excessive carbon dioxide concentration in the chamber is gradually reduced to ≤0.5%.

[0123] 2.2 Drying

[0124] Excessive humidity can cause discomfort for patients undergoing cryotherapy in a cryotherapy chamber. For a completely sealed cryotherapy chamber during treatment, the reasons for increased humidity are: 1. Humidity load of the external environment; 2. Humidity load generated by the human body's metabolic processes. Therefore, the humidity inside the chamber should be controlled during treatment.

[0125] The environmental control system keeps the relative humidity inside the cabin below 30% through drying and CO2 filtration channels.

[0126] The relative humidity sensor HS monitors the relative humidity inside the chamber. When the relative humidity inside the chamber is greater than 25%, the main controller controls the relative humidity to ≤25% by controlling the drying and CO2 filtration channels.

[0127] Air with excessive humidity inside the chamber is heated by the heater HTR to the suction medium temperature range of the low-temperature oil-free air compressor LAC through the chamber ventilation duct CVP-1. It then flows through the oil-free air compressor LAC and through the chamber drying and CO2 filtering solenoid valve SOV-1 (SOV-1 open, SOV-3 closed) to the CO2 filter CO2F, where carbon dioxide is adsorbed. The filtered air then flows to the IN_2 port of the dryer-condenser DCS for further filtration and humidity reduction. The low-humidity air output from the OUT_2 port of the dryer-condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, where its temperature is lowered to the chamber's ambient temperature. It then exits into the chamber through the OUT_2 port of the evaporative heat exchanger EHX-2 (inlet solenoid valve SOV-10 open, enhanced cryotherapy solenoid valve SOV-5 closed). Through the aforementioned drying and CO2 filtration channels, the relative humidity inside the chamber is gradually controlled to ≤25%.

[0128] In summary, according to 2.1 and 2.2, when the relative humidity inside the cabin is greater than 25% or the carbon dioxide concentration inside the cabin is greater than 0.5%, the main control will activate the drying and CO2 filtration channels.

[0129] 3. Environmental replacement channel

[0130] like Figure 7 The bold lines shown represent the environment displacement channel traversal channel.

[0131] The environmental replacement channel typically operates outside of treatment periods, primarily to replace the air within the enclosed cryotherapy chamber to remove airborne particles or substances that cause unpleasant olfactory experiences generated during the treatment of the patient above.

[0132] The oil-free air compressor AC draws pressurized air from the environment, which flows through the chamber displacement solenoid valve SOV-4. The main controller opens SOV-4, directing the pressurized air to the IN_2 port of the dryer-condenser DCS for filtration and drying to reduce humidity. The low-humidity pressurized air from the OUT_2 port of the dryer-condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, lowering its temperature to the chamber's ambient temperature. It then exits through the OUT_2 port of the evaporative heat exchanger EHX-2 back into the chamber (with the inlet solenoid valve SOV-10 open and the enhanced cooling solenoid valve SOV-5 closed).

[0133] To maintain the cabin pressure at the operating pressure, cabin pressure sensor P_1 detects pressure deviations from the operating pressure and initiates cabin depressurization. During depressurization, cabin air flows through cabin ventilation duct CVP-1, is heated by heater HTR to the suction medium temperature range of the low-temperature oil-free air compressor LAC, and is then discharged to the ambient atmosphere via cabin depressurization solenoid valve SOV-3. The operating pressure is the same as the cabin operating pressure described in section 1 (Oxygen Generation Channel): 0.08 MPa.

[0134] 4. Pressure relief channel

[0135] like Figure 8 The bold lines shown represent the pressure relief channel traversal channel.

[0136] The working pressure of the chamber mentioned in section 1, Oxygen Generation Channel, is 0.08 MPa.

[0137] Whether during treatment or not, when the pressure monitored by the chamber pressure sensor P_1 deviates from the working pressure, the chamber pressure relief channel is activated.

[0138] The air inside the cabin is heated to the temperature range of the suction medium of the low-temperature oil-free air compressor LAC by the heater HTR through the cabin ventilation duct CVP-1. The air is then discharged to the ambient atmosphere through the cabin pressure relief solenoid valve SOV-3 by the oil-free air compressor LAC, so that the cabin pressure is maintained at the working pressure (≤0.08Mpa).

[0139] The in-cabin monitoring system includes oxygen sensors, CO2 sensors, pressure sensors, humidity sensors, temperature sensors, and illuminance sensors. It monitors the current values ​​of the treatment parameters and survival parameters to assist in the control of the cooling system, environmental control system, photodynamic therapy system, and portable enhanced therapy system, thereby achieving safe and effective treatment.

[0140] The photodynamic therapy system described is a multi-mode cryotherapy chamber photodynamic light source with a secondary light distribution and distribution structure that reshapes the emitted light. The photodynamic light source inside the chamber is a multi-spectral light source composed of 460nm, 630nm, and 525nm wavelengths. The light source used in the photodynamic therapy system is as follows: multiple multi-wavelength light chips are packaged into the same light source module. The light source module uses a compound eye lens optical system for secondary light distribution to reshape the unevenly distributed incident circular light spot into a uniformly illuminated rectangular light spot. The light source module and the compound eye lens optical system constitute a light source unit. A certain number of light source units with intervals are distributed along the circumference and longitudinal direction of the chamber to form a light source unit array. The light source unit array solves the problems of light intensity, uniformity, and illumination area inside the chamber, enabling patients inside the chamber to receive photodynamic therapy with uniform illumination.

[0141] The portable local enhanced cryotherapy system comprises a portable cryotherapy chamber containing a local enhanced cryotherapy structure that provides enhanced cryotherapy to specific areas of the body during treatment within the chamber. The local enhanced terminal (MLEC), controlled by this structure, treats random locations on the body in the vertical direction. The MLEC's cooling source is an environmental control system, which selects a local enhanced cryotherapy channel before entering the chamber via the system's displacement channel to achieve enhanced cryotherapy. The MLEC can move vertically to provide cryotherapy to random locations on the body in the vertical direction. The MLEC also features an open nozzle to provide enhanced low-temperature spray cryotherapy to specific areas.

[0142] like Figure 9 The bold lines shown represent the traversal channels of locally enhanced cryotherapy.

[0143] The oil-free air compressor AC draws pressurized air from the environment, which flows through the chamber displacement solenoid valve SOV-4. The main controller opens SOV-4, directing the pressurized air to the IN_2 port of the dryer-condenser DCS for filtration and drying to reduce humidity. The low-humidity pressurized air from the OUT_2 port of the dryer-condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, lowering its temperature to the chamber's ambient temperature. It then exits through the OUT_2 port of the evaporative heat exchanger EHX-2 to the portable local enhanced cryotherapy terminal MLEC for local enhanced cryotherapy (inlet solenoid valve SOV-10 is closed, enhanced cryotherapy solenoid valve SOV-5 is open).

[0144] To maintain the cabin pressure at the operating pressure, cabin pressure sensor P_1 detects a deviation from the operating pressure and initiates cabin depressurization. During depressurization, cabin air flows through cabin ventilation duct CVP-1, is heated by heater HTR to the temperature range of the suction medium of the low-temperature oil-free air compressor LAC, and is then discharged to the ambient atmosphere via cabin depressurization solenoid valve SOV-3. The operating pressure is the same as the cabin operating pressure described in section 2.1 (Oxygen Generation Channel), which is 0.08 MPa.

[0145] Example 2

[0146] An oxygen-enriched, multi-mode cryotherapy chamber system includes a refrigeration system, an environmental control system, a movable local enhanced cryotherapy system, an in-chamber monitoring system, a photodynamic therapy system, and a dual-light distribution structure. The refrigeration system, environmental control system, movable local enhanced cryotherapy system, in-chamber monitoring system, and photodynamic therapy system are connected to a main controller. The main controller, according to human-machine interaction settings, acts on each system to achieve cryotherapy combining oxygen-enriched recovery, photodynamic therapy, and local enhanced cryotherapy. The system also includes refrigeration pipes arranged outside the chamber and connected to the refrigeration system, environmental control pipes arranged inside the chamber and connected to the environmental control system, and local cooling pipes arranged inside the chamber and connected to the movable local enhanced cryotherapy system.

[0147] like Figure 2 As shown, the bold lines represent the refrigeration circulation channels of the refrigeration system that enable -110°C cryogenic therapy within the chamber, including the following steps;

[0148] S1; A certain proportion of the non-azeotropic working fluid R290 / R23 / R14 is compressed by the refrigeration compressor RFC into a high-temperature, high-pressure gas, which is then discharged into the condenser CD for phase change condensation. Under the same pressure, the gas-liquid phase change temperatures of the mixed working fluid are different, achieving refrigerant separation. Part of the high-temperature stage working fluid (R290) condenses into a saturated liquid, while most of the medium-temperature stage working fluid (R23) and the low-temperature stage working fluid (R14) remain in a gaseous state. The above gas-liquid mixed working fluid enters the pressure and temperature controlled regenerator PTR, where the high-temperature stage working fluid (R290) is further liquefied, and the medium-temperature stage working fluid (R23) and the low-temperature stage working fluid (R14) are further cooled and remain as superheated vapors.

[0149] S2; The mixed working fluid after passing through the PTR regenerator flows through the gas-liquid separator GLS-1, where it achieves automatic separation of gas and liquid under gravity. The liquefied high-temperature working fluid flows through the bottom liquid phase outlet (L) of the gas-liquid separator GLS-1 to the throttle valve TOF, enters the high-temperature condenser-evaporator CE_HTS, and then mixes with the evaporated gas returning from the IN_2 port of the high-temperature condenser-evaporator CE_HTS. The non-azeotropic mixed gas working fluid output from the gas phase outlet (G) of the gas-liquid separator GLS-1 enters from the IN_1 port of the high-temperature condenser-evaporator CE_HTS and is cooled by the above mixed working fluid.

[0150] S3; After the mixed working fluid is cooled by the high-temperature stage condenser-evaporator CE_HTS, most of the high-temperature stage working fluid condenses into a saturated liquid, while most of the medium-temperature stage working fluid and the low-temperature stage working fluid remain in a gaseous state. The gas-liquid mixed working fluid is output from the OUT_1 port of the high-temperature stage condenser-evaporator CE_HTS and enters the gas-liquid separator GLS-2. Under the action of gravity, the gas and liquid of the mixed working fluid are automatically separated. The liquefied high-temperature stage working fluid flows through the bottom liquid phase outlet (L) of the gas-liquid separator GLS-2 to the electromagnetic throttling valve ETOF-2 in the high-temperature stage electromagnetic throttling valve group ETOF_HTS. The electromagnetic throttling valve ETOF-2 controls the liquefied high-temperature stage working fluid to enter the medium-temperature stage condenser-evaporator CE_MTS.

[0151] S4; The main controller closes the electromagnetic throttle valve ETOF-1 and opens the electromagnetic throttle valve ETOF-2. The liquefied high-temperature working fluid enters the medium-temperature condenser-evaporator CE_MTS and mixes with the evaporated gas returning from the IN_2 port of the medium-temperature condenser-evaporator CE_MTS. The non-azeotropic mixed working fluid output from the gas phase outlet (G) of the gas-liquid separator GLS-2 enters from the IN_1 port of the medium-temperature condenser-evaporator CE_MTS and is cooled by the above mixed working fluid.

[0152] S5; After the mixed working fluid is cooled by the medium-temperature stage condenser-evaporator CE_MTS, most of the medium-temperature stage working fluid condenses into a saturated liquid, while most of the low-temperature stage working fluid remains in a gaseous state; The gas-liquid mixed working fluid output from the OUT_1 port of the medium-temperature stage condenser-evaporator CE_MTS enters the gas-liquid separator GLS-3 and achieves automatic separation of gas and liquid under the action of gravity. The liquefied medium-temperature stage working fluid flows through the bottom liquid phase outlet (L) of the gas-liquid separator GLS-3 to the electromagnetic throttling valve ETOF-5 of the medium-temperature stage electromagnetic throttling valve group ETOF_MTS. The electromagnetic throttling valve ETOF-5 is used to control the entry of the liquefied medium-temperature stage working fluid into the low-temperature stage condenser-evaporator CE_LTS.

[0153] S6; The main controller closes the electromagnetic throttle valve ETOF-4 and opens the electromagnetic throttle valve ETOF-5. The liquefied medium-temperature working fluid enters the low-temperature condenser-evaporator CE_LTS and mixes with the evaporated gas returning from the IN_2 port of the low-temperature condenser-evaporator CE_LTS. The non-azeotropic mixed working fluid output from the gas phase outlet (G) of the gas-liquid separator GLS-3 enters from the IN_1 port of the low-temperature condenser-evaporator CE_LTS and is cooled by the above mixed working fluid.

[0154] S7; After the mixed working fluid is cooled by the low-temperature stage condenser-evaporator CE_MTS, most of the low-temperature stage working fluid (R14) condenses into a saturated liquid; temperature sensor T_5 is used to collect the fluid temperature of the low-temperature stage working fluid (R14) output from the OUT_1 port of the low-temperature stage condenser-evaporator CE_LTS to monitor the refrigeration status. The liquefied low-temperature stage working fluid (R14) flows to the electromagnetic throttling valve ETOF-7. In this embodiment, the electromagnetic throttling valve ETOF-7 is in the open state, and then enters the evaporator heat exchanger EHX-1, evaporator heat exchanger EHX-2 and dryer condenser DCS after passing through the electromagnetic throttling valve.

[0155] S8; EHX-1 evaporative heat exchanger is a refrigeration pipe located outside the cabin, which exchanges heat with the cabin body and gradually reduces the cabin temperature to the saturation temperature of the liquid cryogenic working fluid (R14).

[0156] S9; During the heat exchange process, the liquid low-temperature working fluid (R14) releases cold energy, evaporates into gas, and flows back to the IN_2 port of each stage of condenser-evaporator; Among them, the electromagnetic throttling valve ETOF-3 is used to control the return of the evaporated gas working fluid after passing through the evaporator heat exchanger EHX-1, evaporator heat exchanger EHX-2, and dry condenser DCS to the IN_2 port of the high-temperature stage condenser-evaporator CE_HTS; Among them, the electromagnetic throttling valve ETOF-6 is used to control the return of the evaporated gas working fluid after passing through the evaporator heat exchanger EHX-1, evaporator heat exchanger EHX-2, and dry condenser DCS to the IN_2 port of the medium-temperature stage condenser-evaporator CE_MTS.

[0157] S10; The main controller closes electromagnetic throttle valves ETOF-3 and ETOF-6; the refluxed, evaporated low-temperature working fluid (R14) enters the IN_2 port of the low-temperature condenser-evaporator CE_LTS via the one-way valve OWV and mixes with the liquefied medium-temperature working fluid (R23) before entering the low-temperature condenser-evaporator CE_LTS. The mixed working fluid, after releasing its cooling capacity, flows out through the OUT_2 port of the low-temperature condenser-evaporator CE_LTS, enters the IN_2 port of the medium-temperature condenser-evaporator CE_MTS via the one-way valve OWV, mixes with the liquefied high-temperature working fluid (R290), and enters the medium-temperature condenser-evaporator CE_MTS. The mixed working fluid, after releasing its cooling capacity, flows out through the OUT_2 port of the medium-temperature condenser-evaporator CE_MTS, enters the IN_2 port of the high-temperature condenser-evaporator CE_MTS via the one-way valve OWV, mixes with a small amount of liquefied high-temperature working fluid (R290), and enters the high-temperature condenser-evaporator CE_HTS. After releasing the cooling capacity, the mixed working fluid flows out through OUT_2 of the high-temperature condenser-evaporator CE_HTS and enters the refrigeration compressor RFC for compression, completing the refrigeration cycle.

[0158] The refrigeration cycle described above traverses the refrigeration cycle channel 1, which exchanges heat with the chamber through the liquid cryogenic working fluid (R14) in the evaporator heat exchanger EHX-1, gradually reducing the temperature inside the chamber to the saturation temperature of the liquid cryogenic working fluid (R14), that is, achieving an ultra-low temperature of -110°C in the chamber.

[0159] Example 3

[0160] A multi-mode cryotherapy chamber system with oxygen-enriched synergy includes a refrigeration system, an environmental control system, a movable local enhanced cryotherapy system, an in-chamber monitoring system, a photodynamic therapy system, and a dual-light distribution structure. The refrigeration system, environmental control system, movable local enhanced cryotherapy system, in-chamber monitoring system, and photodynamic therapy system are connected to a main controller. The main controller, based on human-machine interface settings, acts on each system to achieve cryotherapy combining oxygen-enriched recovery, photodynamic therapy, and local enhanced cryotherapy. The system also includes refrigeration pipes located outside the chamber and connected to the refrigeration system, environmental control pipes located inside the chamber and connected to the environmental control system, and local cooling pipes located inside the chamber and connected to the movable local enhanced cryotherapy system.

[0161] like Figure 3 As shown, the bold lines represent the cooling system's traversal of the cooling circulation channel to achieve -80°C cryogenic therapy within the chamber, including the following steps;

[0162] S1; A certain proportion of the non-azeotropic working fluid R290 / R23 / R14 is compressed by the refrigeration compressor RFC into a high-temperature, high-pressure gas, which is then discharged into the condenser CD for phase change condensation. Under the same pressure, the gas-liquid phase change temperatures of the mixed working fluid are different, achieving refrigerant separation. Part of the high-temperature stage working fluid (R290) condenses into a saturated liquid, while most of the medium-temperature stage working fluid (R23) and the low-temperature stage working fluid (R14) remain in a gaseous state. The above gas-liquid mixed working fluid enters the pressure and temperature controlled regenerator PTR, where the high-temperature stage working fluid (R290) is further liquefied, and the medium-temperature stage working fluid (R23) and the low-temperature stage working fluid (R14) are further cooled and remain as superheated vapors.

[0163] S2; The mixed working fluid after passing through the PTR regenerator flows through the gas-liquid separator GLS-1, where it achieves automatic separation of gas and liquid under gravity. The liquefied high-temperature working fluid (R290) flows through the bottom liquid phase outlet (L) of GLS-1 to the throttle valve TOF, and then enters the high-temperature condenser-evaporator, where it mixes with the evaporated gas returning from the IN_2 port of the high-temperature condenser-evaporator CE_HTS. The non-azeotropic mixed working fluid output from the gas phase outlet (G) of the gas-liquid separator GLS-1 enters from the IN_1 port of the high-temperature condenser-evaporator CE_HTS and is cooled by the above mixed working fluid.

[0164] S3; After the mixed working fluid is cooled by the high-temperature stage condenser-evaporator CE_HTS, most of the high-temperature stage working fluid (R290) condenses into a saturated liquid, while most of the medium-temperature stage working fluid (R23) and the low-temperature stage working fluid (R14) remain in a gaseous state. The gas-liquid mixed working fluid output from the OUT_1 port of the high-temperature stage condenser-evaporator CE_HTS enters the gas-liquid separator GLS-2, where the gas and liquid are automatically separated under gravity. The liquefied high-temperature stage working fluid (R290) flows through the bottom liquid phase outlet (L) of GLS-2 to the electromagnetic throttling valve ETOF-2 of the high-temperature stage electromagnetic throttling valve group ETOF_HTS. The electromagnetic throttling valve ETOF-2 controls the liquefied high-temperature stage working fluid (R290) to enter the medium-temperature stage condenser-evaporator CE_MTS.

[0165] S4; The main controller closes the electromagnetic throttle valve ETOF-1 and opens the electromagnetic throttle valve ETOF-2. The liquefied high-temperature working fluid (R290) flows through the bottom liquid phase outlet (L) of GLS-2 to the electromagnetic throttle valve ETOF-2, enters the medium-temperature condenser-evaporator CE_MTS, and mixes with the evaporated gas returning from the IN_2 port of the medium-temperature condenser-evaporator CE_MTS. The non-azeotropic mixed working fluid output from the gas phase outlet (G) of the gas-liquid separator GLS-2 enters from the IN_1 port of the medium-temperature condenser-evaporator CE_MTS and is cooled by the above mixed working fluid.

[0166] S5; After the mixed working fluid is cooled by the intermediate-temperature condenser-evaporator CE_MTS, most of the intermediate-temperature working fluid (R23) condenses into a saturated liquid, while most of the low-temperature working fluid (R14) remains gaseous. The gas-liquid mixture output from the OUT_1 port of the intermediate-temperature condenser-evaporator CE_MTS enters the gas-liquid separator GLS-3, where it automatically separates from the liquid under gravity. Most of the low-temperature working fluid (R14), still in a gaseous state, flows through the top gas phase outlet (G) of GLS-3 to the junction of the pressure and temperature control regenerator PTR branch line and the IN_1 port of the low-temperature condenser-evaporator CE_LTS. In this embodiment, in the refrigeration cycle channel 2, the -80℃ temperature control solenoid valve SOV-8 ​​is open, and most of the cryogenic working fluid (R14), which is still in a gaseous state, flows through the above-mentioned junction point to the throttling pipe OFT-3. After throttling, it enters the pressure vessel PV through SOV-8 ​​and the one-way valve OWV. In the other passage of the junction point, since the throttling solenoid valve ETOF-7 is in a closed state, most of the cryogenic working fluid (R14), which is still in a gaseous state, will not pass through this passage to participate in the refrigeration cycle. The liquefied intermediate-temperature working fluid (R23) flows through the bottom liquid phase outlet (L) of GLS-3 to the electromagnetic throttling valve ETOF-4 of the intermediate-temperature electromagnetic throttling valve group ETOF_MTS.

[0167] S6; The main controller opens the electromagnetic throttling valve ETOF-4 and closes the electromagnetic throttling valve ETOF-5. The liquefied intermediate-temperature working fluid (R23) flows through the bottom liquid phase outlet (L) of GLS-3 to the electromagnetic throttling valve ETOF-4. Temperature sensor T_4 is used to collect the fluid temperature of the intermediate-temperature working fluid (R23) output from the OUT_1 port of the intermediate-temperature condenser-evaporator CE_MTS to monitor the refrigeration status. The liquefied intermediate-temperature working fluid (R23) then enters the evaporator heat exchanger EHX-1, evaporator heat exchanger EHX-2, and dryer condenser DCS via the electromagnetic throttling valve ETOF-4. The evaporator heat exchanger EHX-1 is a refrigeration pipe located outside the cabin, exchanging heat with the cabin body to gradually reduce the cabin temperature to the saturation temperature of the liquid intermediate-temperature working fluid (R23).

[0168] S7; During the heat exchange process, the liquid intermediate temperature working fluid (R23) releases cold energy, evaporates into gas, and flows back to the IN_2 port of each stage of condenser-evaporator.

[0169] S8; The main controller closes the electromagnetic throttling valve ETOF-3 and opens the electromagnetic throttling valve ETOF-6. The refluxed, low-temperature intermediate-temperature working fluid (R23) enters the IN_2 port of the low-temperature condenser-evaporator CE_LTS via the one-way valve OWV and the IN_2 port of the intermediate-temperature condenser-evaporator CE_MTS via the electromagnetic throttling valve ETOF-6, where it mixes with the liquefied high-temperature working fluid (R290) and enters the intermediate-temperature condenser-evaporator CE_MTS. The mixed working fluid, after releasing its cooling capacity, flows out through the OUT_2 port of the intermediate-temperature condenser-evaporator CE_MTS, enters the IN_2 port of the high-temperature condenser-evaporator CE_MTS via the one-way valve OWV, and mixes with a small amount of liquefied high-temperature working fluid (R290) before entering the high-temperature condenser-evaporator CE_HTS. After releasing the cooling capacity, the mixed working fluid flows out through OUT_2 of the high-temperature condenser-evaporator CE_HTS and enters the return channel of the refrigeration compressor RFC. The working fluid entering the return channel through this channel is mainly gaseous high-temperature working fluid (R290) and gaseous medium-temperature working fluid (R23). In the refrigeration cycle channel 2 of the embodiment, before entering the refrigeration compressor RFC, a branch channel on the return channel is connected to the pressure vessel PV. The pressure vessel PV contains most of the low-temperature working fluid (R14) that remains in a gaseous state during this refrigeration cycle, which enters through the pressure and temperature control regenerator PTR and is controlled by the -80°C temperature control solenoid valve SOV-8. By controlling the opening and closing of the discharge pressure control solenoid valve SOV-9, most of the low-temperature working fluid (R14) that remains in a gaseous state in the pressure vessel PV enters the return channel through the throttling pipe OFT-4, mixes with the gaseous high-temperature working fluid (R290) and gaseous medium-temperature working fluid (R23), and then enters the refrigeration compressor RFC for compression, completing the refrigeration cycle.

[0170] The cooling cycle described in the above embodiment traverses the cooling cycle channel 2. Through the liquid intermediate temperature working fluid (R23) in the evaporator heat exchanger EHX-1, heat is exchanged with the chamber, gradually reducing the temperature inside the chamber to the saturation temperature of the liquid intermediate temperature working fluid (R23), that is, achieving an ultra-low temperature of -80°C in the chamber.

[0171] Example 4

[0172] An oxygen-enriched, multi-mode cryotherapy chamber system includes a refrigeration system, an environmental control system, a movable local enhanced cryotherapy system, an in-chamber monitoring system, a photodynamic therapy system, and a dual-light distribution structure. The refrigeration system, environmental control system, movable local enhanced cryotherapy system, in-chamber monitoring system, and photodynamic therapy system are connected to a main controller. The main controller, according to human-machine interaction settings, acts on each system to achieve cryotherapy combining oxygen-enriched recovery, photodynamic therapy, and local enhanced cryotherapy. The system also includes refrigeration pipes arranged outside the chamber and connected to the refrigeration system, environmental control pipes arranged inside the chamber and connected to the environmental control system, and local cooling pipes arranged inside the chamber and connected to the movable local enhanced cryotherapy system.

[0173] like Figure 4 As shown, the bold lines represent the cooling system's traversal of the cooling circulation channel to achieve -40°C cryogenic therapy within the chamber, including the following steps;

[0174] S1; A certain proportion of the non-azeotropic working fluid R290 / R23 / R14 is compressed by the refrigeration compressor RFC into a high-temperature, high-pressure gas, which is then discharged into the condenser CD for phase change condensation. Under the same pressure, the different phase change temperatures of the gas and liquid phases of the working fluid achieve refrigerant separation. Part of the high-temperature stage working fluid (R290) condenses into a saturated liquid, while most of the medium-temperature stage working fluid (R23) and the low-temperature stage working fluid (R14) remain in a gaseous state. The above gas-liquid mixture enters the pressure and temperature controlled regenerator PTR, where the high-temperature stage working fluid (R290) is further liquefied, and the medium-temperature stage working fluid (R23) and the low-temperature stage working fluid (R14) are further cooled and remain as superheated vapors.

[0175] S2; The mixed working fluid after passing through the PTR regenerator flows through the gas-liquid separator GLS-1, where it achieves automatic separation of gas and liquid under gravity. The liquefied high-temperature working fluid (R290) flows through the bottom liquid phase outlet (L) of GLS-1 to the throttle valve TOF, and then enters the high-temperature condenser-evaporator CE_HTS, where it mixes with the evaporated gas returning from the IN_2 port of the high-temperature condenser-evaporator CE_HTS. The non-azeotropic mixed gas working fluid output from the gas phase outlet (G) of the gas-liquid separator GLS-1 is cooled by the above-mentioned mixed working fluid through the IN_1 port of the high-temperature condenser-evaporator CE_HTS.

[0176] S3; After the mixed working fluid is cooled by the high-temperature stage condenser-evaporator CE_HTS, most of the high-temperature stage working fluid (R290) condenses into a saturated liquid, while most of the medium-temperature stage working fluid (R23) and the low-temperature stage working fluid (R14) remain in a gaseous state. The gas-liquid mixed working fluid output from the OUT_1 port of the high-temperature stage condenser-evaporator CE_HTS enters the gas-liquid separator GLS-2, where the gas and liquid are automatically separated under gravity. Most of the medium-temperature stage working fluid (R23) and the low-temperature stage working fluid (R14), which are still in a gaseous state, flow through the top gas phase outlet (G) of GLS-2 to the junction point of the pressure and temperature control regenerator PTR branch line and the medium-temperature stage condenser-evaporator CE_MTS's IN_1 port. When the -40℃ temperature control solenoid valve SOV-7 is open, most of the gaseous intermediate-temperature refrigerant (R23) and cryogenic refrigerant (R14) flow through the above-mentioned junction to the throttling pipe OFT-2. After throttling, they enter the pressure vessel PV through SOV-7 and the one-way valve OWV. Because the throttling solenoid valve ETOF-7 is closed, most of the gaseous intermediate-temperature refrigerant (R23) and cryogenic refrigerant (R14) will not participate in the refrigeration cycle through this other passage.

[0177] S4; The liquefied high-temperature working fluid (R290) flows through the bottom liquid phase outlet (L) of GLS-2 to the electromagnetic throttling valve ETOF-1 of the high-temperature electromagnetic throttling valve group ETOF_HTS.

[0178] S5; The main controller opens electromagnetic throttle valve ETOF-1 and closes electromagnetic throttle valve ETOF-2. The liquefied high-temperature working fluid (R290) flows through the bottom liquid phase outlet (L) of GLS-2 to electromagnetic throttle valve ETOF-1. Temperature sensor T_3 is used to collect the fluid temperature of the high-temperature working fluid (R290) output from the OUT_1 port of the high-temperature condenser-evaporator CE_HTS to monitor the refrigeration status. The liquefied high-temperature working fluid (R290) then enters evaporator heat exchanger EHX-1, evaporator heat exchanger EHX-2, and dryer condenser DCS via electromagnetic throttle valve ETOF-1. Evaporator heat exchanger EHX-1 is a refrigeration pipe located outside the cabin, exchanging heat with the cabin body to gradually reduce the cabin temperature to the saturation temperature of the liquid high-temperature working fluid (R290). During the heat exchange process, the liquid high-temperature working fluid (R290) releases cold energy, evaporates into gas, and flows back to the IN_2 port of each stage of condenser-evaporator.

[0179] S6; The main controller opens the electromagnetic throttle valve ETOF-3 and closes the electromagnetic throttle valve ETOF-6. The refluxed, evaporated, high-temperature working fluid (R290) enters the IN_2 port of the low-temperature condenser-evaporator CE_LTS via the one-way valve OWV and the IN_2 port of the high-temperature condenser-evaporator CE_HTS via the electromagnetic throttle valve ETOF-3. It mixes with a small portion of the liquefied high-temperature working fluid (R290) and enters the high-temperature condenser-evaporator CE_HTS. The mixed working fluid, after releasing its cooling capacity, flows out through the OUT_2 port of the high-temperature condenser-evaporator CE_HTS and enters the return channel of the refrigeration compressor RFC. The working fluid entering the return channel through this path is mainly the gaseous high-temperature working fluid (R290). In the embodiment, the refrigeration cycle channel 3 is connected to the pressure vessel PV via a branch passage on the return channel before entering the refrigeration compressor RFC. The pressure vessel PV contains most of the gaseous intermediate-temperature working fluid (R23) and low-temperature working fluid (R14) that enter the refrigeration cycle through the pressure and temperature control regenerator PTR and are controlled by the -40°C temperature control solenoid valve SOV-7.

[0180] S7; By controlling the opening and closing of the solenoid valve SOV-9, most of the gaseous intermediate-temperature working fluid (R23) and low-temperature working fluid (R14) in the pressure vessel PV enter the return channel through the throttling pipe OFT-4, mix with the gaseous high-temperature working fluid (R290), and then enter the refrigeration compressor RFC for compression, completing the refrigeration cycle.

[0181] The cooling cycle described in the above embodiment traverses the cooling cycle channel 3, which exchanges heat with the chamber through the liquid high-temperature working fluid (R290) in the evaporative heat exchanger EHX-1, gradually reducing the temperature inside the chamber to the saturation temperature of the liquid high-temperature working fluid (R290), that is, achieving an ultra-low temperature of -40°C in the chamber.

[0182] The foregoing has shown and described the basic principles, main features, and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The embodiments and descriptions in the specification are merely preferred examples and are not intended to limit the invention. Various changes and modifications can be made to the present invention without departing from its novel spirit and scope, and all such changes and modifications fall within the scope of the present invention as claimed. The scope of protection of the present invention is defined by the appended claims and their equivalents.

Claims

1. A multi-mode cryotherapy chamber system with oxygen-enriched synergy, characterized in that, It includes a refrigeration system, an environmental control system, a portable local enhanced cryotherapy system, an in-cabin monitoring system, a photodynamic therapy system, and a dual-light distribution structure. The refrigeration system, environmental control system, portable local enhanced cryotherapy system, in-cabin monitoring system, and photodynamic therapy system are connected to the main controller. The main controller, according to the human-machine interaction settings, acts on each system to achieve ultra-low temperature cryotherapy that combines oxygen-enriched recovery, photodynamic therapy, and local enhanced cryotherapy. It also includes refrigeration pipes arranged outside the cabin and connected to the refrigeration system, environmental control pipes arranged inside the cabin and connected to the environmental control system, and local cooling pipes arranged inside the cabin and connected to the portable local enhanced cryotherapy system. The environmental control system is a closed-loop cryotherapy chamber environment control system. The chamber itself is physically isolated from the surrounding environment, forming a completely enclosed physical space. During treatment, the environmental control system manages the environment within this completely enclosed space. The patient is situated within this space, and the environmental control measures treatment and survival parameters to ensure safe and effective treatment. Treatment parameters include temperature, light intensity, treatment time, and oxygen levels. Survival parameters include carbon dioxide concentration, humidity, and chamber pressure. These parameters are controlled through system operating modes, including oxygen generation, drying, and... The oxygen generation mode includes filtration mode, environmental replacement mode, and depressurization mode. The oxygen generation mode consists of an oxygen generation channel, drying, and... Filtration modes consist of drying and The system consists of a filtration channel, an environmental replacement mode consisting of an environmental replacement channel, and a pressure relief mode consisting of a pressure relief channel. The oxygen generation channel, drying channel, and... The filtration channel and the environmental replacement channel are both channels for outside gas to enter the cabin. They share an evaporative heat exchanger and a drying condenser to cool and dry the gas in the pipeline. The pressure relief channel is the channel for the gas inside the cabin to be discharged from the cabin. The environmental control system maintains the oxygen concentration within the chamber within an oxygen-enriched range, specifically between 21% and 24%, through the oxygen generation channel. After the oxygen-enriched concentration is designed via human-machine interface, the oxygen concentration sensor (OS) monitors changes in the chamber's oxygen concentration and maintains the oxygen concentration at the set level by controlling the oxygen generation channel. The environmental control system also utilizes the drying and... The filtration system controls the relative humidity inside the chamber to below 30%; the relative humidity sensor HS monitors the relative humidity inside the chamber, and when the relative humidity inside the chamber exceeds 25%, the main controller activates the drying and... The filtration channel controls the relative humidity to ≤25%; the environmental replacement channel operates during non-treatment periods, primarily replacing the air within the enclosed cryotherapy chamber to remove airborne particles or substances causing unpleasant olfactory experiences generated during treatment by the patient; the refrigeration system employs single-stage compression to achieve a wide temperature range of -40℃ to -110℃, using a mixture of different refrigerants to form a multi-component refrigerant. The different boiling points of these mixed refrigerants, under the same pressure, allow for refrigerant separation; the mixed refrigerant is a non-azeotropic working fluid, compressed and discharged by the single-stage compressor before entering the condenser-evaporator for cooling. The mixed working fluid condenses and forms a multiphase flow with the uncondensed working fluid. The multiphase fluid is separated by a gas-liquid separator. The mixed working fluid with different boiling points enters a condenser-evaporator at different temperature levels and is then condensed to form a high-temperature liquid stage working fluid, a medium-temperature liquid stage working fluid, and a low-temperature liquid stage working fluid. The liquid working fluid evaporates in the evaporator, achieving heat absorption and cooling. The different liquid working fluids formed after passing through the high-temperature gas-liquid separator and the low-temperature condenser-evaporator enter the terminal evaporator to achieve different cooling temperatures. The evaporator covers the outside of the enclosed chamber and, through heat exchange, can lower the temperature inside the chamber to within -40℃ to -110℃. The cryotherapy chamber is a completely enclosed physical space during treatment. Low-temperature, low-humidity, pressurized oxygen enters the chamber, increasing the internal pressure. During treatment, the internal pressure of the sealed cryotherapy chamber is maintained at ≤0.08 MPa, i.e., the working pressure is 0.08 MPa, which is considered an atmospheric pressure vessel. To maintain the internal pressure at the working pressure during oxygen production, the internal pressure sensor P_1 monitors the pressure and initiates internal pressure release when it deviates from the working pressure. During pressure release, the air inside the chamber passes through the internal ventilation pipe CVP-1, is heated by the heater HTR to the temperature range of the suction medium of the low-temperature oil-free air compressor LAC, and is then discharged to the ambient atmosphere through the internal pressure release solenoid valve SOV-3 of the oil-free air compressor LAC.

2. The oxygen-enriched synergistic multi-mode cryotherapy chamber system according to claim 1, characterized in that, The cabin monitoring system includes an oxygen sensor, Sensors, including pressure, humidity, temperature, and illuminance sensors, monitor the current values ​​of treatment and survival parameters to assist in the control of the cooling system, environmental control system, photodynamic therapy system, and mobile enhanced therapy system, thereby achieving safe and effective treatment.

3. The oxygen-enriched synergistic multi-mode cryotherapy chamber system according to claim 1, characterized in that, The photodynamic therapy system is a multi-mode cold therapy chamber photodynamic light source secondary light distribution and distribution structure to achieve the shaping of the emitted light from the light source. The photodynamic light source in the chamber is a multi-spectral light source composed of 460nm, 630nm and 525nm. The light source form adopted by the photodynamic therapy system in the chamber is as follows: multiple multi-wavelength light chips are packaged into the same light source module. The light source module performs secondary light distribution through a compound eye lens optical system to shape the unevenly distributed incident circular light spot into a uniformly illuminated rectangular light spot. The light source module and the compound eye lens optical system constitute a light source unit. The light source units are distributed at intervals along the circumference and longitudinal direction of the chamber to form a light source unit array.

4. The oxygen-enriched synergistic multi-mode cryotherapy chamber system according to claim 1, characterized in that, The portable local enhanced cryotherapy system utilizes a local enhanced cryotherapy structure within a portable cryotherapy chamber to provide enhanced cryotherapy to specific areas of the body during treatment within the chamber. The local enhanced terminal, controlled by this structure, performs treatment at random locations along the vertical direction of the body. The cooling source for the local enhanced terminal (MLEC) originates from an automated control system. It selects a local enhanced cryotherapy channel before entering the chamber via a replacement channel from the environmental control system to achieve local enhanced cryotherapy. The portable local enhanced cryotherapy terminal has an open nozzle.

5. The oxygen-enriched synergistic multi-mode cryotherapy chamber system according to claim 4, characterized in that, The environmental control system maintains the oxygen concentration within the chamber within an oxygen-enriched range, typically between 21% and 24%, via an oxygen generation channel. After the oxygen-enriched concentration is designed via human-machine interface, the oxygen concentration sensor (OS) monitors changes in the chamber's oxygen concentration and maintains the set concentration by controlling the oxygen generation channel. The oxygen generator (OG) draws air from the environment, passes it through an internal molecular sieve, and outputs pressurized oxygen at a concentration controlled at 93% ± 3%. This oxygen flows through the chamber's electrically adjustable solenoid valve (SOV-2), and the main controller adjusts the valve accordingly. The opening of the SOV-2 valve controls the oxygen flow rate of the oxygen generation channel; the pressurized oxygen, after the flow rate is controlled, flows to the IN_2 port of the dryer condenser DCS to filter and dry the oxygen and reduce its humidity; the low-humidity pressurized oxygen output from the OUT_2 port of the dryer condenser DCS flows to the IN_2 port of the evaporative heat exchanger EHX-2, reducing the temperature of the low-humidity pressurized oxygen to the ambient temperature inside the chamber, and then outputs it into the chamber through the OUT_2 port of the evaporative heat exchanger EHX-2. The chamber inlet solenoid valve SOV-10 is opened, and the enhanced cryotherapy solenoid valve SOV-5 is closed.

Images